Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-05-23
2006-05-23
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S312000, C514S235500, C514S253070, C514S228200, C544S128000, C544S363000, C544S062000, C546S153000, C540S553000
Reexamination Certificate
active
07049309
ABSTRACT:
This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome.
REFERENCES:
patent: 5892045 (1999-04-01), Sit et al.
patent: 5922735 (1999-07-01), Sit et al.
patent: 5972961 (1999-10-01), Hewawasam et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6353119 (2002-03-01), Crispino et al.
patent: 6538022 (2003-03-01), Pollesello et al.
patent: 2002371078 (2002-12-01), None
patent: WO 02/26713 (2002-04-01), None
P. Hewawasam, et al., “4-Aryl-3-(mercapto)quinolin-2-ones: Novel Maxi-K channnel opening relaxants of corporal smooth muscle,” Bioorg. & Med. Chem. Lett., 14(17), pp. 4479-4482, 2004.
P. Hewawasam, et al, “4-Aryl-3-(Hydroxyalkyl)Quinolin-2-Ones: Novel Maxi-K Channel Opening Relaxants of Corporal Smooth Muscle Targeted for Erectile Dysfunction,” J. Med. Chem., 46, pp. 2819-2822, 2003.
Boy Kenneth M.
Hewawasam Piyasena
Sit Sing-Yuen
Xie Kai
Barker Michael P.
Bristol--Myers Squibb Company
Epperson James
Saeed Kamal A.
LandOfFree
3-Thia-4-arylquinolin-2-one potassium channel modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-Thia-4-arylquinolin-2-one potassium channel modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-Thia-4-arylquinolin-2-one potassium channel modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526761